CCL8 Antibody

What is CCL8 and why is it a significant target for immunological research?

CCL8, also known as Monocyte Chemotactic Protein 2 (MCP-2), is a member of the CC-subfamily of chemokines most closely related to CCL2 (MCP-1) and CCL7 (MCP-3). These proteins are secreted by various cell types in response to inflammatory stimuli and play critical roles in recruiting leukocytes to areas of inflammation. While all three MCP proteins function as potent chemoattractants for monocytes and T cells, CCL8 specifically attracts NK cells, eosinophils, and basophils, though it requires higher concentrations compared to CCL7 to achieve this effect. CCL8 signals primarily through the G protein-coupled receptor CCR5, which is shared with other CC-chemokines and notably serves as the primary co-receptor for HIV entry via the gp120 envelope protein . Recent studies have also implicated CCL8 in acute respiratory distress syndrome in severe COVID-19 cases, highlighting its clinical significance as a potential therapeutic target .

What types of CCL8 antibodies are available and how should researchers choose between them?

Researchers have several options when selecting CCL8 antibodies, primarily categorized as monoclonal or polyclonal antibodies with various conjugations:

When selecting an antibody, researchers should consider the specific application, species reactivity, and whether functional blocking is required. For flow cytometry applications, pre-titrated conjugated antibodies like the DWZEE monoclonal antibody may be optimal, while for ELISA applications, polyclonal antibodies might provide better sensitivity .

What are the standard validation steps necessary before implementing CCL8 antibodies in critical research?

Before implementing CCL8 antibodies in critical research, comprehensive validation is essential to ensure experimental rigor:

• Specificity testing: Cross-reactivity assessment against related chemokines, particularly CCL2 and CCL7, should be performed due to their structural similarity to CCL8.

• Positive and negative controls: Include CCL8-overexpressing cells as positive controls and CCL8 knockout cells or tissues (e.g., from CCL8KO mice) as negative controls .

• Concentration optimization: Titrate antibody concentrations in relevant applications. For flow cytometry, start with manufacturer recommendations (e.g., 5 μL (0.125 μg) per test for the DWZEE antibody) .

• Signal-to-noise ratio assessment: Evaluate background staining versus specific signal across different antibody concentrations.

• Intra- and inter-assay variation: Test reproducibility across multiple experiments and batches.

• Functional validation for neutralizing antibodies: Confirm the antibody's ability to inhibit CCL8-mediated effects using chemotaxis assays or inflammatory cytokine measurements .

What are the optimal protocols for intracellular staining of CCL8 in flow cytometry applications?

For optimal intracellular staining of CCL8 using flow cytometry, researchers should follow this methodological approach:

• Cell preparation: Isolate target cells (e.g., peripheral blood monocytes) using standard isolation techniques. Ensure viability is >95% for optimal results.

• Stimulation (optional): For enhanced CCL8 detection, stimulate cells with appropriate inflammatory stimuli (e.g., LPS, cytokines) depending on research question.

• Surface marker staining: If performing multi-parameter analysis, first stain surface markers using appropriate antibodies before fixation.

• Fixation/permeabilization: Use a commercial fixation/permeabilization kit compatible with chemokine detection. Chemokines may be sensitive to certain fixation methods.

• Blocking: Incubate with Fc receptor blocking reagent to reduce non-specific binding.

• Antibody staining: For the DWZEE monoclonal antibody (eFluor 660 conjugated), use 5 μL (0.125 μg) per test (defined as the amount of antibody needed to stain a cell sample in 100 μL final volume). Cell numbers should be empirically determined but typically range from 10^5 to 10^8 cells/test .

• Washing: Perform at least two washing steps with permeabilization buffer.

• Controls: Include fluorescence minus one (FMO) controls, isotype controls, and positive controls (stimulated cells known to express CCL8).

• Acquisition: When using eFluor 660-conjugated antibodies, ensure your instrument has a red laser (633 nm) for excitation, as eFluor 660 emits at 659 nm .

• Analysis: Use appropriate gating strategies to identify CCL8-positive cells. Consider co-staining with macrophage markers if investigating M2 macrophage relationships .

How can CCL8 antibodies be effectively used in both in vitro and in vivo experimental designs?

CCL8 antibodies can serve multiple functions in both in vitro and in vivo experimental designs:

In vitro applications:

• Protein detection: Use in Western blot, ELISA, or immunocytochemistry to quantify CCL8 expression in cell culture supernatants or cell lysates .

• Functional studies: Neutralizing antibodies like 1G3E5 can block CCL8 activity to study downstream effects on chemotaxis, inflammatory response, or receptor signaling .

• Receptor binding studies: CCL8 antibodies can be used to investigate the interaction between CCL8 and its receptors (CCR1, CCR2, CCR3, CCR5, CCR8) .

• Co-localization studies: Fluorescently conjugated CCL8 antibodies combined with receptor antibodies can visualize receptor-ligand interactions using confocal microscopy.

In vivo applications:

• Therapeutic potential assessment: Neutralizing CCL8 antibodies like 1G3E5 can be administered to animal models to evaluate potential therapeutic effects. Studies in LPS-induced lung injury models demonstrated that inhibition of CCL8 activity reduced pulmonary inflammation and suppressed pro-inflammatory cytokines .

• Pharmacokinetic considerations: When administering CCL8 antibodies in vivo, consider the administration route. Research indicates that intraperitoneal (IP) administration maintained higher antibody levels for longer periods compared to intravenous (IV) administration .

• Experimental controls: Include appropriate controls such as isotype-matched antibodies and genetic models (e.g., CCL8KO mice) for comparison .

• Delivery optimization: For respiratory studies, consider whether nebulized, intranasal, or systemic administration is most appropriate based on the target tissue .

What considerations are important when studying CCL8 in relation to its multiple receptors (CCR1, CCR2, CCR3, CCR5, and CCR8)?

When investigating CCL8 in relation to its multiple receptors, researchers should consider several methodological aspects:

• Receptor expression profiling: Before conducting functional studies, characterize the expression of CCL8 receptors (CCR1, CCR2, CCR3, CCR5, and CCR8) in your experimental system. Research has shown that CCR2 and CCR5 expression is significantly stimulated in LPS-induced lung injury models .

• Receptor specificity: Design experiments that distinguish between receptor subtypes, as CCL8 signals through multiple receptors. Consider using receptor-specific antagonists or knockout models alongside CCL8 antibodies.

• Receptor co-regulation analysis: Analyze the co-expression patterns of different CCRs. Studies have shown that chemokine receptors are highly co-regulated in response to inflammatory stimuli like LPS, suggesting coordinated expression .

• CCL8-independent receptor regulation: Monitor receptor expression independently of CCL8 levels. In some cases, CCL8 expression may not change during inflammation while receptor expression increases significantly, altering the system's sensitivity to existing CCL8 .

• Temporal dynamics: Consider the kinetics of both CCL8 and receptor expression, as they may follow different time courses during inflammatory responses.

• HIV research considerations: When studying CCL8 in the context of HIV, focus on the CCL8-CCR5 interaction, as CCR5 serves as the primary co-receptor for HIV entry. CCL8 can inhibit viral entry both through steric hindrance of gp120-CCR5 interaction and through ligand-mediated receptor internalization .

How can CCL8 antibodies be used to investigate the role of CCL8 in acute respiratory conditions, including COVID-19?

CCL8 antibodies represent powerful tools for investigating respiratory pathologies, particularly given the recent findings linking CCL8 to COVID-19 severity:

• Differential expression analysis: Use CCL8 antibodies in immunohistochemistry or flow cytometry to compare CCL8 expression in lung tissue or bronchoalveolar lavage fluid from patients with varying degrees of respiratory distress. Recent studies have shown that CCL8 is significantly stimulated during acute respiratory distress syndrome in severely ill COVID-19 patients .

• Neutralization studies in animal models: Administer neutralizing CCL8 antibodies (like 1G3E5) in models of respiratory infection or LPS-induced lung injury to assess potential therapeutic effects. Research has demonstrated that CCL8 inhibition reduces pulmonary inflammation and suppresses various pro-inflammatory cytokines in such models .

• Mechanistic pathway analysis: Combine CCL8 antibody neutralization with assessment of downstream inflammatory mediators. Research has revealed that CCL8 inhibition disrupts the CCL8-TNFα network, leading to reduced TNFα expression and decreased pulmonary inflammation .

• Receptor interaction studies: Use CCL8 antibodies alongside analysis of receptor expression (particularly CCR2 and CCR5, which are significantly upregulated in LPS-induced lung injury) to understand how receptor dynamics contribute to disease progression .

• Cellular infiltration assessment: Analyze how CCL8 neutralization affects immune cell recruitment to the lungs using flow cytometry of bronchoalveolar lavage samples. Histological assessment has shown moderate inhibition of inflammation in the lungs of CCL8-deficient mice challenged with LPS .

• Translational research considerations: When designing studies with potential clinical applications, consider using both genetic models (CCL8KO mice) and antibody-mediated approaches, as the acute inhibition of CCL8 may have more pronounced effects than constitutive deficiency .

What is the relationship between CCL8 and M2 macrophages in cancer research, and how can antibodies help elucidate this connection?

The relationship between CCL8 and M2 macrophages in cancer, particularly in diffuse large B-cell lymphoma (DLBCL), represents an important area of investigation:

• Co-expression analysis: Utilize CCL8 antibodies alongside M2 macrophage markers (e.g., CD163) in immunofluorescence or flow cytometry studies. Research has identified CD163 and CCL8 as hub genes with distinct prognostic associations in DLBCL .

• Tumor microenvironment characterization: Apply CCL8 antibodies to analyze the spatial distribution of CCL8-expressing cells relative to M2 macrophages in tumor tissue sections. Studies have shown that abundant M2 macrophages are present in high-CCL8 expression groups in DLBCL .

• Functional intervention studies: Use neutralizing CCL8 antibodies to assess the impact on M2 macrophage recruitment, polarization, and function in tumor models. This approach can help determine whether the CCL8-M2 macrophage relationship is causal or merely correlative.

• Prognostic significance assessment: Correlate CCL8 expression (detected with antibodies) with clinical outcomes and M2 macrophage infiltration. Research has suggested that CCL8 may serve as a promising prognostic factor in DLBCL through its interaction with M2 macrophages .

• Immune checkpoint correlation: Analyze the relationship between CCL8 expression, M2 macrophage infiltration, and immune checkpoint molecules like PD-L1 and CTLA4. Higher CCL8 expression has been associated with better follow-up status and higher expression of these immune checkpoint molecules in some cancer contexts .

• Therapeutic targeting strategies: Investigate whether dual targeting of CCL8 and M2 macrophages offers synergistic anti-tumor effects compared to targeting either component alone.

How should researchers interpret contradictory findings when using CCL8 antibodies across different experimental models?

When encountering contradictory findings in CCL8 antibody-based research across different models, consider these methodological approaches for reconciliation:

• Species-specific differences: The low homology between human and mouse CCL8 (71%) can lead to discrepancies between models. For example, the antigenic peptide used for the development of the 1G3E5 antibody shares only 6 out of 14 amino acid identities between human and mouse . Consider using models with higher CCL8 ortholog similarity to human CCL8 when translational relevance is important.

• Context-dependent CCL8 regulation: In some inflammatory contexts, CCL8 expression may not change significantly while its receptors are upregulated. For instance, in LPS-induced lung injury, CCL8 expression was not enhanced by LPS, while CCR2 and CCR5 receptors were significantly stimulated . This suggests a "permissive" rather than "inductive" role for CCL8 in some contexts.

• Genetic background effects: Consider using outbred animal models to assess antibody effects in genetically diverse populations. Studies have employed outbred deer mice rather than conventional inbred laboratory mice to better reflect human population diversity .

• Constitutive versus acute inhibition differences: Genetic knockout models (CCL8KO) may show different effects compared to acute antibody-mediated inhibition. Research has suggested that acute inhibition of CCL8 may have more pronounced effects during acute lung injury than constitutive deficiency .

• Antibody mechanism considerations: Beyond neutralization, CCL8 antibodies may cause depletion of CCL8-positive cells or downregulation of CCL8 expression. When interpreting results, consider which mechanism predominates in your experimental system .

• Timing of intervention: The temporal relationship between CCL8 inhibition and disease progression may explain contradictory findings. Design time-course experiments to determine optimal intervention points.

What are the critical quality control parameters for maintaining CCL8 antibody performance in long-term research projects?

Maintaining antibody quality throughout long-term research projects is essential for reproducible results. Consider these critical quality control parameters:

• Storage conditions: Store CCL8 antibodies according to manufacturer recommendations. Most antibodies should be stored at -20°C, and aliquoting is generally unnecessary for -20°C storage. For antibodies like the polyclonal Ccl8 antibody (51110-1-AP), the recommended storage buffer is PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Freeze-thaw cycles: Minimize freeze-thaw cycles by creating working aliquots appropriate for your experimental needs, especially for antibodies that are sensitive to repeated freezing and thawing.

• Lot-to-lot variability assessment: When receiving a new lot of antibody, perform side-by-side comparisons with the previous lot using standard samples to ensure consistent performance.

• Periodic revalidation: Even with established antibodies, perform regular validation tests to confirm continued specificity and sensitivity:

  • For flow cytometry applications: Include positive controls (e.g., stimulated monocytes known to express CCL8)

  • For neutralizing antibodies: Verify continued functional blocking activity

• Stability monitoring: If using conjugated antibodies (like the eFluor 660-conjugated DWZEE monoclonal antibody), regularly check for photobleaching or fluorophore degradation, particularly if stored for extended periods.

• Documentation: Maintain detailed records of antibody performance over time, including:

  • Signal intensity in standardized assays

  • Background levels

  • Optimal working concentrations

  • Any troubleshooting performed

• Reference standards: Maintain long-term reference samples (where possible) that can be used to calibrate antibody performance across the duration of the project.

What alternative approaches should be considered when CCL8 antibody-based detection yields inconsistent results?

When facing inconsistent results with CCL8 antibody-based detection, researchers should consider these alternative approaches:

• Multi-antibody validation: Use multiple antibodies targeting different epitopes of CCL8. Compare results between monoclonal antibodies (like DWZEE) and polyclonal antibodies to distinguish between technical and biological variability .

• Orthogonal detection methods:

  • mRNA quantification: Use RT-qPCR to measure CCL8 transcript levels alongside protein detection

  • Recombinant protein standards: Include recombinant CCL8 protein standards to calibrate detection sensitivity

  • Mass spectrometry: For unbiased protein identification when antibody specificity is in question

• Genetic controls: Include CCL8 knockout samples as negative controls and CCL8-overexpressing systems as positive controls to establish the dynamic range of detection .

• Alternative fixation/permeabilization methods: For intracellular staining, test different fixation and permeabilization protocols, as chemokines can be sensitive to particular fixation methods.

• Signal amplification techniques:

  • For immunohistochemistry: Consider tyramide signal amplification

  • For flow cytometry: Evaluate secondary antibody approaches if using unconjugated primary antibodies

• Receptor-based detection: Instead of direct CCL8 detection, measure CCL8 activity through receptor-based assays such as CCR5 internalization or calcium flux assays.

• Biological activity assays: Assess CCL8 functional activity through chemotaxis assays or reporter cell lines expressing CCL8 receptors, which may provide more relevant information than absolute protein levels.

How can researchers optimize CCL8 antibody-based assays for detecting low-abundance CCL8 in clinical specimens?

Detecting low-abundance CCL8 in clinical specimens requires optimized approaches:

• Sample preparation optimization:

  • For blood samples: Consider density gradient separation for cellular components

  • For tissue samples: Evaluate different extraction methods to maximize CCL8 recovery

  • For bronchoalveolar lavage: Standardize collection volumes and concentration techniques

• Pre-analytical considerations:

  • Sample collection timing: CCL8 levels may fluctuate during disease progression

  • Preservation methods: Determine optimal fixation for tissue or stabilization for fluids

  • Storage conditions: Establish protocols that prevent degradation

• Signal enhancement strategies:

  • Concentration of samples: Use ultrafiltration or precipitation techniques

  • Enzymatic signal amplification: Consider enzyme-linked detection systems

  • For flow cytometry: Use brighter fluorophores with optimal signal-to-noise ratios

• Assay sensitivity improvements:

  • For ELISA: Develop sandwich ELISA using the polyclonal antibody (51110-1-AP) for capture and a distinct antibody for detection

  • Increase antibody incubation times: Allow for equilibrium binding in low-abundance conditions

  • Reduce background: Optimize blocking conditions and increase washing stringency

• Multiplexed approaches:

  • Measure CCL8 alongside related chemokines (CCL2, CCL7) and receptors (CCR2, CCR5)

  • Include internal normalization controls specific to each sample type

• Digital detection methods:

  • Single molecule array (Simoa) technology for ultra-sensitive protein detection

  • Digital ELISA platforms with enhanced sensitivity thresholds

• Clinical correlation:

  • Correlate CCL8 levels with disease markers to establish clinically meaningful thresholds

  • Design longitudinal sampling to capture dynamic changes in individual patients

By implementing these optimization strategies, researchers can enhance the detection of low-abundance CCL8 in clinical specimens, facilitating more accurate assessment of its role in various pathological conditions.